342 related articles for article (PubMed ID: 26022079)
1. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
Hu L; Zheng Y; Li Z; Wang Y; Lv Y; Qin X; Zeng C
Bioorg Med Chem; 2015 Jul; 23(13):3147-52. PubMed ID: 26022079
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
Hu L; Cao T; Lv Y; Ding Y; Yang L; Zhang Q; Guo M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5830-5835. PubMed ID: 28029512
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Li Y; Shen M; Zhang Z; Luo J; Pan X; Lu X; Long H; Wen D; Zhang F; Leng F; Li Y; Tu Z; Ren X; Ding K
J Med Chem; 2012 Nov; 55(22):10033-46. PubMed ID: 23088644
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of pyridin-3-yl pyrimidines as potent Bcr-Abl inhibitors.
Pan X; Dong J; Gao H; Wang F; Zhang Y; Wang S; Zhang J
Chem Biol Drug Des; 2014 May; 83(5):592-9. PubMed ID: 24330598
[TBL] [Abstract][Full Text] [Related]
5. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
[TBL] [Abstract][Full Text] [Related]
7. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel Bcr-Abl
Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J
Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitumor activities of some new N1-(flavon-6-yl)amidrazone derivatives.
Habashneh AY; El-Abadelah MM; Zihlif MA; Imraish A; Taha MO
Arch Pharm (Weinheim); 2014 Jun; 347(6):415-22. PubMed ID: 24615985
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
[TBL] [Abstract][Full Text] [Related]
11. Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
Shan Y; Dong J; Pan X; Zhang L; Zhang J; Dong Y; Wang M
Eur J Med Chem; 2015 Nov; 104():139-47. PubMed ID: 26451772
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC
J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156
[TBL] [Abstract][Full Text] [Related]
13. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.
Mojzych M; Šubertová V; Bielawska A; Bielawski K; Bazgier V; Berka K; Gucký T; Fornal E; Kryštof V
Eur J Med Chem; 2014 May; 78():217-24. PubMed ID: 24681986
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules.
Cao R; Wang Y; Huang N
J Chem Inf Model; 2015 Nov; 55(11):2435-42. PubMed ID: 26501568
[TBL] [Abstract][Full Text] [Related]
17. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
Li S; Yao Z; Zhao Y; Chen W; Wang H; Kuang X; Zhan W; Yao S; Yu S; Hu W
Bioorg Med Chem Lett; 2012 Aug; 22(16):5279-82. PubMed ID: 22789429
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.
Radi M; Tintori C; Musumeci F; Brullo C; Zamperini C; Dreassi E; Fallacara AL; Vignaroli G; Crespan E; Zanoli S; Laurenzana I; Filippi I; Maga G; Schenone S; Angelucci A; Botta M
J Med Chem; 2013 Jul; 56(13):5382-94. PubMed ID: 23746084
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.
Altıntop MD; Ciftci HI; Radwan MO; Sever B; Kaplancıklı ZA; Ali TFS; Koga R; Fujita M; Otsuka M; Özdemir A
Molecules; 2017 Dec; 23(1):. PubMed ID: 29280989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
